87,386 Shares in ADMA Biologics Inc $ADMA Acquired by Freestone Grove Partners LP

Freestone Grove Partners LP acquired a new position in shares of ADMA Biologics Inc (NASDAQ:ADMA) during the second quarter, HoldingsChannel.com reports. The firm acquired 87,386 shares of the biotechnology company’s stock, valued at approximately $731,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ADMA. Summit Securities Group LLC purchased a new position in shares of ADMA Biologics during the 4th quarter worth $29,000. iSAM Funds UK Ltd acquired a new position in shares of ADMA Biologics during the 3rd quarter valued at about $34,000. Morse Asset Management Inc purchased a new stake in shares of ADMA Biologics in the fourth quarter valued at about $44,000. EverSource Wealth Advisors LLC grew its holdings in shares of ADMA Biologics by 385.8% in the second quarter. EverSource Wealth Advisors LLC now owns 2,745 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 2,180 shares during the period. Finally, Smartleaf Asset Management LLC increased its position in ADMA Biologics by 28.9% during the second quarter. Smartleaf Asset Management LLC now owns 3,118 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 700 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Price Performance

Shares of ADMA opened at $9.34 on Monday. The firm has a market cap of $2.09 billion, a P/E ratio of 13.34 and a beta of 0.74. ADMA Biologics Inc has a 12-month low of $7.21 and a 12-month high of $20.46. The company’s 50-day moving average price is $9.07 and its 200 day moving average price is $10.50. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting analysts’ consensus estimates of $0.16. The company had revenue of $124.39 million for the quarter, compared to analysts’ expectations of $125.34 million. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. ADMA Biologics’s revenue for the quarter was up 2.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.14 earnings per share. On average, sell-side analysts forecast that ADMA Biologics Inc will post 0.78 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on ADMA shares. Raymond James Financial assumed coverage on shares of ADMA Biologics in a research note on Wednesday, June 10th. They set an “outperform” rating and a $21.00 target price on the stock. Mizuho cut their price target on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, July 15th. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Finally, Canaccord Genuity Group decreased their price objective on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $18.67.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.